Literature DB >> 1176071

[A case of "membranous lipodystrophy (Nasu)" with emphasis on psychiatric and neuropathologic aspects (author's transl)].

K Harada.   

Abstract

A housewife, 42 years old, died from a chronic progressive neuro-psychiatric illness of 15 years duration characterized by memory disturbance, moria-syndrome, euphoria, social disorder and extrapyramidal symptoms combined with a severe bone disease. Pathologically, the adipose tissue in bone marrow, and also in other body areas such as the periadrenal region and renal pelvis showed a characteristic degeneration with "membranous cycle" structures. Neuropathological examination showed an extensive atrophy of cerebral white matter, especially in the frontal and temporal lobes, with a marked fibrillary gliosis, a moderate destruction of myelin sheath without grossly visible distinct demyelination and with a relatively normal cerebral cortex: a picture resembling sclerosing leukoencephalopathy. From these findings the case was identified as "membranous lipodystrophy--Nasu." Moreover, the case may be related to the "lipomembranous polycystic osteodysplasia with progressive dementia" of Järvi, Hakola et. al. In cases with an unknown atrophic illness of cerebral white matter there should be carried out a pathological examination of adipose tissue, especially of the bone marrow.

Entities:  

Mesh:

Year:  1975        PMID: 1176071

Source DB:  PubMed          Journal:  Folia Psychiatr Neurol Jpn        ISSN: 0015-5721


  12 in total

Review 1.  Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia.

Authors:  A Verloes; P Maquet; B Sadzot; M Vivario; A Thiry; G Franck
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

2.  Nasu-Hakola's disease (membranous lipodystrophy).

Authors:  N Amano; K Iwabuchi; H Sakai; S Yagishita; Y Itoh; E Iseki; S Yokoi; N Arai; J Kinoshita
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

3.  Ultrastructural demonstration of Maclura pomifera agglutinin binding sites in the membranocystic lesions of membranous lipodystrophy (Nasu-Hakola disease).

Authors:  I Kitajima; T Suganuma; F Murata; K Nagamatsu
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

4.  Membranous lipodystrophy. A case report.

Authors:  T Matsuo; M Suetsugu; M Eguchi; M Sasaki; M Tsuneyoshi
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

5.  Radiologic bone changes of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy.

Authors:  P Mäkelä; O Järví; P Hakola; P Virtama
Journal:  Skeletal Radiol       Date:  1982       Impact factor: 2.199

6.  Nasu-Hakola's disease (membranous lipodystrophy). A case report.

Authors:  M Matsushita; S Oyanagi; S Hanawa; H Shiraki; K Kosaka
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

7.  Leukoencephalopathic alteration in membranous lipodystrophy.

Authors:  J Tanaka
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

8.  Ultrastructural lipid and glycoconjugate cytochemistry of membranous lipodystrophy (Nasu-Hakola disease).

Authors:  Y Mii; Y Miyauchi; T Yoshikawa; K Honoki; M Aoki; M Tsutsumi; H Maruyama; M Funauchi; Y Konishi; S Tamai
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

9.  Membranocystic lesions of the lung in Nasu-Hakola disease.

Authors:  S Yagishita; Y Ito; H Sakai; N Amano
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

Review 10.  Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects.

Authors:  Marino Muxfeldt Bianchin; Heraldo M Capella; Daniel Loureiro Chaves; Mário Steindel; Edmundo C Grisard; Gerson Gandi Ganev; João Péricles da Silva Júnior; Schaeffer Neto Evaldo; Mônica Aparecida Poffo; Roger Walz; Carlos G Carlotti Júnior; Américo C Sakamoto
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.